Studies have compared sitagliptin with GLP-1 receptor agonists in drug naïve subjects with type 2 diabetes [exenatide, (110)] or as add on to other therapy for exenatide (111), semaglutide (112), albiglutide (113), and dulaglutide (114). Here, GLP1R is linked to type 2 diabetes mellitus.